| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | DBDR, DRD1B, DRD1L2 |
| WB Predicted band size | 53 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human DRD5 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于DRD5抗体的3篇参考文献示例(注：以下内容为模拟生成，实际文献需通过学术数据库查询)：
1. **文献名称**：*"Selective antibody-based detection of dopamine D5 receptors in mammalian brain tissue"*
**作者**：Miller, E.K., et al.
**摘要**：研究开发了一种高特异性DRD5抗体，通过免疫组织化学和Western blot验证其在啮齿类和非人类灵长类动物脑组织中的选择性，确认其与DRD1无交叉反应，为研究DRD5的神经分布提供工具。
2. **文献名称**：*"Dopamine D5 receptor antibody validation in human postmortem prefrontal cortex: implications for psychiatric disorders"*
**作者**：Chen, L., & Williams, S.M.
**摘要**：通过对比人脑前额叶皮层样本的DRD5抗体染色结果与mRNA表达数据，验证抗体的可靠性，并发现DRD5蛋白表达水平在精神分裂症患者中显著降低。
3. **文献名称**：*"Characterization of a novel DRD5 monoclonal antibody for flow cytometry applications"*
**作者**：Rodriguez, J.A., et al.
**摘要**：报道了一种适用于流式细胞术的DRD5单克隆抗体，验证其在活细胞表面的结合能力，并应用于分析DRD5在淋巴细胞亚群中的表达差异。
4. **文献名称**：*"Cross-reactivity pitfalls of dopamine receptor antibodies: A case study on DRD5"*
**作者**：Thompson, R., et al.
**摘要**：系统评估了市售DRD5抗体的特异性，发现部分抗体与DRD1或非目标蛋白存在交叉反应，强调验证步骤的必要性，并提出标准化实验方案。
(注：以上文献信息为示例性质，实际引用请以真实出版物为准。)
The dopamine receptor D5 (DRD5) is a member of the dopamine receptor family, classified as a G protein-coupled receptor (GPCR) within the D1-like subfamily (D1 and D5). It is encoded by the DRD5 gene and is distinguished by its high basal activity and ligand-independent signaling. Structurally, DRD5 shares homology with DRD1 but has a longer third intracellular loop, which may influence G protein coupling. Functionally, DRD5 primarily couples to Gαs proteins, activating adenylate cyclase and increasing intracellular cAMP levels upon dopamine binding. It is expressed in key brain regions, including the hippocampus, prefrontal cortex, and hypothalamus, implicating roles in cognition, emotion, and neuroendocrine regulation.
DRD5 antibodies are essential tools for studying the receptor's localization, expression levels, and signaling mechanisms. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and flow cytometry to visualize DRD5 in tissues or cultured cells. Specificity validation via knockout controls or blocking peptides is critical due to potential cross-reactivity with DRD1. Research involving DRD5 antibodies has explored its involvement in neurological and psychiatric disorders, such as schizophrenia, attention-deficit/hyperactivity disorder (ADHD), and addiction, as well as its interplay with other dopamine receptors. Recent studies also investigate DRD5's role in non-neural tissues, such as renal and immune systems, broadening its physiological relevance.
×
